Articles tagged with Multiple Sclerosis
Researchers at Scripps Research Institute developed a cutting-edge technology to screen human blood for disease markers. The 'antigen surrogate' method accurately identified biomarkers for neuromyelitis optica, a rare autoimmune disorder, in a recent study published in Chemistry & Biology.
Researchers have found that atrophy of the thalamus is a key predictor of clinically definite multiple sclerosis (MS) in patients. Thalamic atrophy can help identify patients at risk for developing MS, allowing clinicians to diagnose earlier and monitor disease progression.
A team of scientists identified a novel mechanism by which CD4 T cells expressing NKG2C can target brain cells in Multiple Sclerosis patients. This discovery could lead to improved treatments aiming to decrease disease progression and symptoms, without the risk of potentially lethal infections.
Researchers from Kessler Foundation share progress in rehabilitation research for individuals with multiple sclerosis and stroke, highlighting potential benefits of pharmacological agents, brain stimulation, and aerobic exercise. These studies investigate cognitive complications and explore strategies to improve outcomes.
A controlled clinical trial found that interventional endovascular therapy for multiple sclerosis (MS) does not improve patient outcomes. The treatment was safe but made symptoms worse in some cases. The study's findings lead to caution against the general acceptance of this invasive procedure for MS patients.
A large-scale trial by The Mount Sinai Medical Center found that combination therapy did not improve clinical benefits over single drug treatment in multiple sclerosis patients, but reduced the development of new lesions. Combination therapy with Glatiramer Acetate and Interferon Beta-1a showed a reduction in MRI lesion accumulation.
A recent clinical trial found that combining interferonβ-1a and glatiramer acetate did not reduce relapse risk in multiple sclerosis patients, but reduced new lesion activity and total lesion volume. The study enrolled 1,008 participants over three years.
A study examining people with MS treated with natalizumab and diagnosed with PML found those without symptoms at diagnosis had improved survival and disability levels. Early detection of the disease may mitigate its consequences, allowing for better patient outcomes.
A new study found that adrenocorticotropic hormone (ACTH) may be effective in treating people with breakthrough multiple sclerosis. Participants who received ACTH had fewer relapses and no psychiatric side effects, compared to those receiving methylprednisolone.
Researchers at UTHealth found CCSVI occurs at a low rate in people with multiple sclerosis and non-MS volunteers. The study suggests CCSVI is unlikely to be the cause of MS or contribute to disease worsening.
Researchers at Yale School of Medicine found that dietary salt can induce and worsen pathogenic immune system responses in mice, leading to a more severe form of multiple sclerosis. They discovered the key molecular pathway involved in this response and proposed regulatory networks that govern autoimmune disease.
A study published in Neurology found that people with multiple sclerosis (MS) who experience memory and attention issues have significant damage to brain areas critical for cognitive functions. This discovery has important implications for the diagnosis and treatment of MS-related cognitive problems.
Researchers at Benaroya Research Institute found that IL-6 signaling pathway proteins may serve as novel biomarkers for MS disease activity and a potential therapeutic target. The study discovered that T cells in patients with active MS were more sensitive to IL-6, which could lead to new therapies targeting the IL-6 pathway.
A new study published by the American Academy of Neurology found that obesity may increase the risk of developing multiple sclerosis (MS) in children and teenage girls. The research, which analyzed data from over 913,000 children, found a significant association between obesity and MS in girls, but not in boys.
Researchers discovered that Tip-dendritic cells activate naive CD8+ T cells to recognize myelin protein, leading to autoimmune reactivity. This finding sheds light on the complex role of CD8+ T cells in multiple sclerosis pathology.
Deimination, a protein modification altered in patients with MS and PMD, is reduced in both human patients and mouse models experiencing vision loss. Restoration of deimination improves visual function in mice, suggesting it as a potential therapeutic target for demyelinating diseases.
A study published in Neurology found that people with MS relapses had faster retinal thinning than those without relapses. The study also showed that participants with worsening disability experienced increased retinal thinning.
A recent review of cannabis extract, Sativex, found limited trial data and a lack of comparison to other treatments, casting doubt on its effectiveness for managing multiple sclerosis (MS) symptoms. The review also highlighted the high cost of Sativex compared to other MS medications.
A recent study from Queen Mary University of London has identified two proteins, Egr2 and Egr3, as crucial regulators of the immune response. In patients with multiple sclerosis (MS), T lymphocytes show defective production of these proteins, leading to increased inflammation.
Researchers aim to build cognitive reserve in MS patients by engaging in intellectually stimulating activities, such as reading and puzzle-solving, using iPads. The one-year pilot project will examine improvements in cognitive performance and correlations with changes in neural networks.
Kessler Foundation marks 20 years of promoting inclusivity and accessibility through rehabilitation research and training. Researchers collaborate with global partners to develop innovative interventions for people with disabilities, including stroke, multiple sclerosis, spinal cord injury, and brain injury.
Researchers at Gladstone Institutes have identified a key underlying process implicated in MS, offering new hope for therapies to treat the disease. The discovery reveals that a protein called fibrinogen sets off an immune response in the brain, leading to nerve cell damage and debilitating symptoms.
Dr. John DeLuca, Vice President for Research and Training at Kessler Foundation, is recognized for his pioneering work in cognitive rehabilitation and MS research. He aims to restore and maintain cognitive function through innovative methods and collaborations with international partners.
Researchers find that leakage of fibrinogen into the central nervous system activates immune cells called microglia, leading to nerve damage. Targeting the interaction between fibrinogen and microglia may be an effective alternative for treating multiple sclerosis.
Researchers discovered a molecule called sncRNA715 that suppresses myelin basic protein synthesis, crucial for myelin formation. This finding may help explain myelination failures in neurological illnesses like multiple sclerosis.
A new study aims to determine driving fitness in individuals with multiple sclerosis using a simple and accurate testing protocol. The test, developed by GHSU researcher Dr. Abiodun Akinwuntan, has shown promise in predicting pass or fail outcomes on a road test with 91 percent accuracy.
Researchers identify new therapeutic approaches for acute myeloid leukemia (AML), find immune cells defective in Huntington's disease, and discover signaling pathways contributing to muscle weakness in myotonic dystrophy. Targeting C/EBPG and C/EBPA, or normalizing GSK3β activity may help treat these conditions.
A study found that pregnant women with higher levels of vitamin D in their blood had a 61% lower risk of developing multiple sclerosis, compared to those with low levels. However, the mother's vitamin D level did not affect her child's risk of developing MS.
Researchers have identified a key biochemical marker for cognitive impairment in MS brains and developed an experimental compound to manipulate it, improving learning and memory in mice. The finding has the potential to speed development of new drugs for treating cognitive impairment in MS patients and those with Alzheimer's disease.
Researchers at UCSF discover an 'immune exchange' between the brain and blood that allows disease-causing B cells to move in and out of the brain, providing a potential key to unlocking better treatments and diagnostics. The study suggests that targeting specific B cells could lead to precision therapies tailored to each patient's needs.
A biodegradable nanoparticle has been shown to halt multiple sclerosis in mice by tricking the immune system into stopping its attack on myelin. This technology also shows promise for treating Type 1 diabetes and airway allergies such as asthma.
Researchers have developed a novel treatment that selectively inhibits the part of the immune system responsible for attacking myelin, reducing inflammation in autoimmune disorders like MS. The therapy uses microscopic particles to induce tolerance in animal models, showing potential for treating MS, type I diabetes, and food allergies.
A new MRI model reveals why images are sensitive to nerve fiber direction and allows for detailed information about fiber size and direction. This discovery will help clinicians recognize lesions and tailor scans to patients with specific needs.
Researchers at OHSU have discovered that blocking a specific enzyme can promote myelin-forming cell differentiation and remyelination in MS patients, potentially leading to improved nerve cell function. The discovery could be a 'life-changer' for millions with MS and other demyelinating diseases.
A new MS drug, alemtuzumab, has been shown to significantly reduce the number of attacks and disease activity in patients who have already failed to respond to other treatments. The study also found that alemtuzumab improved disability outcomes, with most patients experiencing an improvement in their condition.
A monoclonal antibody called alemtuzumab shows promise in reducing MS disease activity, with nearly half as many relapses as a common current treatment. The drug also appears to improve disability outlook, particularly in refractory patients who have not responded to previous treatments.
Researchers at Simon Fraser University have identified 475,806 genetic variants in the human genome that contribute to a 30% risk of developing Multiple Sclerosis. These variants, particularly those on chromosome 6, are linked to small DNA variations that have long been associated with MS susceptibility.
A five-minute eye scan can accurately assess brain damage in people with multiple sclerosis, predicting disease progression. The scan uses optical coherence tomography to measure retinal tissue health, providing valuable information for doctors and patients.
Researchers found that strokes among people under 55 increased from 13% to 19% over time, and the average age of people who experienced stroke fell from 71 years to 69 years. Lifestyle changes such as diet and exercise can modify risk factors for stroke.
Researchers have identified a new therapy that appears to stop inflammation in the eye nerves and spinal cord for patients with neuromyelitis optica (NMO), a debilitating central nervous system disorder. The treatment, eculizumab, was given to patients with severe symptoms, resulting in 12 symptom-free periods and two mild attacks.
Abhijit Das, a postdoctoral fellow at Kessler Foundation, was named to the NIDRR-sponsored ARRT Young Investigators Panel for his research on cognitive fatigue in multiple sclerosis. His work aims to convert knowledge about brain networks underlying fatigue into treatment protocols using non-invasive brain stimulation.
Researchers have identified a molecule that plays a crucial role in the development of experimental autoimmune encephalitis (EAE) in MS animal models. Blocking this molecule reduces inflammation and reverses clinical signs of the disease.
Researchers found that women with multiple sclerosis who undergo assisted reproduction technology are at risk for increased disease activity. Sex hormones and reproductive hormones contribute to the regulation of immune responses in autoimmune diseases like MS.
A new study by Johns Hopkins Medicine reveals a strong correlation between low vitamin D levels and increased brain lesions in people with multiple sclerosis. Higher vitamin D levels were associated with lower risk of new lesions and active disease spots.
A new study by researchers at Brigham and Women's Hospital distinguishes multiple sclerosis patients into two meaningful subsets, MSa and MSb, based on distinct RNA molecules. This categorization may lead to more personalized treatments for individual patients.
Jelana Stojanovic, a Kessler Foundation postdoctoral fellow, received the Research Award for Best Poster at the 2012 MS Centers Meeting. Her study used fNIRS to evaluate working memory performance in people with and without multiple sclerosis.
Dr. Chiaravalloti discusses the potential of functional MRI and behavioral therapies to target cognitive deficits in MS patients. Research suggests that these approaches may be effective in improving learning, memory, and processing speed in individuals with MS.
A new study published in Neurology says Gingko biloba does not improve cognitive performance in people with multiple sclerosis. The research followed up on earlier findings that suggested there may be some benefit, but found no cognitive benefits to using the supplement.
A study by Dr. Jesus Lovera and colleagues found that Ginkgo biloba does not improve cognitive function in people with Multiple Sclerosis, contradicting earlier small studies. The researchers suggest that the supplement may be beneficial earlier in the disease process or for participants with more severe impairments.
A new MRI study reveals that vein abnormalities do not contribute to multiple sclerosis (MS) severity and are not specific to the disease. Despite previous speculation, the researchers found no correlation between cerebral blood flow and MS symptoms.
Researchers found that immune cells called dendritic cells protect against multiple sclerosis by reducing T cell responsiveness and increasing PD-1 receptor expression. This discovery could lead to the development of new treatments for the disease.
Researchers at Stanford Medicine discovered that A-beta, a molecule linked to Alzheimer's disease, reverses paralysis and inflammation in mouse models of multiple sclerosis. The findings suggest potential new treatments for the autoimmune disease.
A new study by NIH researchers reveals that lymphoid tissue inducer (LTi) cells contribute to multiple sclerosis, and daclizumab appears to reduce their numbers. The drug also activates natural killer cells, which counteract autoimmunity.
Dr. John DeLuca, VP of Research at Kessler Foundation, received the 2012 Roger G. Barker Distinguished Research Contribution Award from the American Psychological Association for his groundbreaking research on cognitive effects of brain injury and multiple sclerosis. The award recognizes his lifelong contributions to rehabilitation psy...
A study published in Journal of Neuroimmunology suggests that B cells, a type of immune cell, produce toxic substances that damage myelin and contribute to the progression of multiple sclerosis. Researchers hope to identify these substances to develop targeted therapies for MS treatment.
The report explores successful partnerships between employers and disability service organizations to hire workers with disabilities. Successful initiatives include Walgreens Distribution Centers, Lowe's Bridges to Business program, and Walmart's partnership with Project SEARCH.
A study found that interferon beta treatment did not slow disease progression in patients with relapsing-remitting MS. The researchers compared patients treated with interferon beta to those without treatment, but did not find a significant difference in disability progression.
A study of 2656 BC patients found no strong evidence that beta interferons prescribed for relapsing-remitting multiple sclerosis slowed long-term disability progression. Researchers emphasize the need for individualized treatment approaches and further studies on novel treatments.
A new study published in Radiology found that sodium accumulation in the brain correlates directly with disability in multiple sclerosis patients. The research used 3 Tesla sodium MRI to detect abnormal sodium concentrations in specific brain regions and throughout the whole brain.
Research by Jesus Lovera and colleagues found that stress management therapy prevented new brain lesions in people with multiple sclerosis, with 77% of patients remaining free of lesions. The benefit did not continue beyond treatment, highlighting the need for longer therapy or continued support.